Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ijpharm.2021.120686 http://scihub22266oqcxt.onion/10.1016/j.ijpharm.2021.120686 33964339!8099545!33964339     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Pharm 2021 ; 603 (ä): 120686 Nephropedia Template TP {{tp|p=33964339|t=2021. Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?|pdf=|usr=}}{{33964339}} gab.com Text Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines JO: Int J Pharm http://www.kidney.de/pget.php?&tw=1&pmid=33964339 #FOAvip It is striking that all marketed SARS-CoV-2 vaccines are developed for intramuscular administration designed to produce humoral and cell mediated immune responses, preventing viremia and the COVID-19 syndrome. They have a high degree of efficacy in humans (70-95%) depending on the type of vaccine. However, little protection is provided against viral replication and shedding in the upper airways due to the lack of a local sIgA immune response, indicating a risk of transmission of virus from vaccinated individuals. A range of novel nasal COVID-19 vaccines are in development and preclinical results in non-human primates have shown a promising prevention of replication and shedding of virus due to the induction of mucosal immune response (sIgA) in upper and lower respiratory tracts as well as robust systemic and humoral immune responses. Whether these results will translate to humans remains to be clarified. An IM prime followed by an IN booster vaccination would likely result in a better well-rounded immune response, including prevention (or strong reduction) in viral replication in the upper and lower respiratory tracts. Twit Text FOAVip Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines ????Int J Pharm http://www.kidney.de/pget.php?&tw=1&pmid=33964339 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33964339 #FOAvip English Wikipedia <ref>{{Cite pmid|33964339}}</ref> Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines? #MMPMID33964339 Tiboni M; Casettari L; Illum L Int J Pharm 2021[Jun]; 603 (ä): 120686 PMID33964339show ga It is striking that all marketed SARS-CoV-2 vaccines are developed for intramuscular administration designed to produce humoral and cell mediated immune responses, preventing viremia and the COVID-19 syndrome. They have a high degree of efficacy in humans (70-95%) depending on the type of vaccine. However, little protection is provided against viral replication and shedding in the upper airways due to the lack of a local sIgA immune response, indicating a risk of transmission of virus from vaccinated individuals. A range of novel nasal COVID-19 vaccines are in development and preclinical results in non-human primates have shown a promising prevention of replication and shedding of virus due to the induction of mucosal immune response (sIgA) in upper and lower respiratory tracts as well as robust systemic and humoral immune responses. Whether these results will translate to humans remains to be clarified. An IM prime followed by an IN booster vaccination would likely result in a better well-rounded immune response, including prevention (or strong reduction) in viral replication in the upper and lower respiratory tracts. |*COVID-19[MESH] |*SARS-CoV-2[MESH] |Antibodies, Viral[MESH] |COVID-19 Vaccines[MESH] |Humans[MESH] |Immunity, Humoral[MESH]Nasal vaccination against SARS-CoV-2: Synergistic or alternative to in(epmc).pdf DeepDyve Pubget Overpricing